AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
Bridging the Access Divide in Relapsed DLBCL: Lessons from James’s Journey
By Dr. Nandita Khera
A case-based look at relapsed diffuse large B-cell lymphoma (DLBCL) highlighting barriers to CAR-T and bispecific antibody access and how care coordination, early referral, and system redesign can improve equitable treatment delivery.
Bridging the Access Divide in Relapsed DLBCL: Lessons from James’s Journey
By Dr. Nandita Khera
A case-based look at relapsed diffuse large B-cell lymphoma (DLBCL) highlighting barriers to CAR-T and bispecific antibody access and how care coordination, early referral, and system redesign can improve equitable treatment delivery.
Bridging the Access Divide in Relapsed DLBCL: Lessons from James’s Journey
By Dr. Nandita Khera
A case-based look at relapsed diffuse large B-cell lymphoma (DLBCL) highlighting barriers to CAR-T and bispecific antibody access and how care coordination, early referral, and system redesign can improve equitable treatment delivery.
Top Clinical Takeaways from SABCS 2025: What Oncologists Need to Know Now
By Zunairah Shah, MD; Shipra Gandhi, MD, MS
Key practice-changing insights from SABCS 2025, including earlier use of antibody–drug conjugates, the rise of oral SERDs, mutation-guided endocrine therapy, and evolving treatment sequencing across breast cancer subtypes.
Top Clinical Takeaways from SABCS 2025: What Oncologists Need to Know Now
By Zunairah Shah, MD; Shipra Gandhi, MD, MS
Key practice-changing insights from SABCS 2025, including earlier use of antibody–drug conjugates, the rise of oral SERDs, mutation-guided endocrine therapy, and evolving treatment sequencing across breast cancer subtypes.
Top Clinical Takeaways from SABCS 2025: What Oncologists Need to Know Now
By Zunairah Shah, MD; Shipra Gandhi, MD, MS
Key practice-changing insights from SABCS 2025, including earlier use of antibody–drug conjugates, the rise of oral SERDs, mutation-guided endocrine therapy, and evolving treatment sequencing across breast cancer subtypes.
“They Told Me It’s Stage 4.” Does Stage 4 Cancer Always Mean the End?
By Matthew Meranda, DO
A stage 4 cancer diagnosis is serious—but not always terminal. Dr. Matthew Meranda explains what stage 4 means, how metastatic cancer is treated today, and how patients can navigate prognosis and communication with their care team.
“They Told Me It’s Stage 4.” Does Stage 4 Cancer Always Mean the End?
By Matthew Meranda, DO
A stage 4 cancer diagnosis is serious—but not always terminal. Dr. Matthew Meranda explains what stage 4 means, how metastatic cancer is treated today, and how patients can navigate prognosis and communication with their care team.
“They Told Me It’s Stage 4.” Does Stage 4 Cancer Always Mean the End?
By Matthew Meranda, DO
A stage 4 cancer diagnosis is serious—but not always terminal. Dr. Matthew Meranda explains what stage 4 means, how metastatic cancer is treated today, and how patients can navigate prognosis and communication with their care team.
Dr. Gentry King on Advances in Hepatocellular Carcinoma and Biliary Tract Cancers: From Targeted Therapy to Advanced Treatment Strategies
By The Cancer News Team
Dr. Gentry King reviews the latest advances in hepatocellular carcinoma and biliary tract cancers, highlighting FGFR2-targeted therapy, immune checkpoint inhibitors, and evolving strategies across BCLC stages.
Dr. Gentry King on Advances in Hepatocellular Carcinoma and Biliary Tract Cancers: From Targeted Therapy to Advanced Treatment Strategies
By The Cancer News Team
Dr. Gentry King reviews the latest advances in hepatocellular carcinoma and biliary tract cancers, highlighting FGFR2-targeted therapy, immune checkpoint inhibitors, and evolving strategies across BCLC stages.
Dr. Gentry King on Advances in Hepatocellular Carcinoma and Biliary Tract Cancers: From Targeted Therapy to Advanced Treatment Strategies
By The Cancer News Team
Dr. Gentry King reviews the latest advances in hepatocellular carcinoma and biliary tract cancers, highlighting FGFR2-targeted therapy, immune checkpoint inhibitors, and evolving strategies across BCLC stages.
Dr. Rachael A. Safyan on Pancreatic Cancer: Evolving Treatment Paradigms from Resectable to Metastatic Disease
By The Cancer News Team
Dr. Rachael A. Safyan reviews evolving treatment strategies in pancreatic cancer, from neoadjuvant therapy and tumor-treating fields to RAS-targeted agents reshaping metastatic care.
Dr. Rachael A. Safyan on Pancreatic Cancer: Evolving Treatment Paradigms from Resectable to Metastatic Disease
By The Cancer News Team
Dr. Rachael A. Safyan reviews evolving treatment strategies in pancreatic cancer, from neoadjuvant therapy and tumor-treating fields to RAS-targeted agents reshaping metastatic care.
Dr. Rachael A. Safyan on Pancreatic Cancer: Evolving Treatment Paradigms from Resectable to Metastatic Disease
By The Cancer News Team
Dr. Rachael A. Safyan reviews evolving treatment strategies in pancreatic cancer, from neoadjuvant therapy and tumor-treating fields to RAS-targeted agents reshaping metastatic care.
Dr. David Zhen Discusses Advances in Neuroendocrine Tumor Treatment: From Emerging Systemic Therapies to Next-Generation Radioligand Strategies
By The Cancer News Team
Dr. David Zhen reviews major advances in neuroendocrine tumor treatment, including cabozantinib approval, earlier use of PRRT, emerging alpha-emitter radioligand therapies, and novel targeted agents.
Dr. David Zhen Discusses Advances in Neuroendocrine Tumor Treatment: From Emerging Systemic Therapies to Next-Generation Radioligand Strategies
By The Cancer News Team
Dr. David Zhen reviews major advances in neuroendocrine tumor treatment, including cabozantinib approval, earlier use of PRRT, emerging alpha-emitter radioligand therapies, and novel targeted agents.
Dr. David Zhen Discusses Advances in Neuroendocrine Tumor Treatment: From Emerging Systemic Therapies to Next-Generation Radioligand Strategies
By The Cancer News Team
Dr. David Zhen reviews major advances in neuroendocrine tumor treatment, including cabozantinib approval, earlier use of PRRT, emerging alpha-emitter radioligand therapies, and novel targeted agents.
Dr. Emerson Y. Chen on Perioperative Chemoimmunotherapy and HER2-Directed Therapies in Resectable and Advanced Gastric Cancer
By The Cancer News Team
Dr. Emerson Y. Chen reviews MATTERHORN, HERIZON-GEA-01, and DESTINY-Gastric04, highlighting perioperative nivolumab plus FLOT and next-generation HER2-directed therapies in advanced gastroesophageal cancer.
Dr. Emerson Y. Chen on Perioperative Chemoimmunotherapy and HER2-Directed Therapies in Resectable and Advanced Gastric Cancer
By The Cancer News Team
Dr. Emerson Y. Chen reviews MATTERHORN, HERIZON-GEA-01, and DESTINY-Gastric04, highlighting perioperative nivolumab plus FLOT and next-generation HER2-directed therapies in advanced gastroesophageal cancer.
Dr. Emerson Y. Chen on Perioperative Chemoimmunotherapy and HER2-Directed Therapies in Resectable and Advanced Gastric Cancer
By The Cancer News Team
Dr. Emerson Y. Chen reviews MATTERHORN, HERIZON-GEA-01, and DESTINY-Gastric04, highlighting perioperative nivolumab plus FLOT and next-generation HER2-directed therapies in advanced gastroesophageal cancer.
Why Indigenous Communities Face Higher Cancer Rates
By Jin Mou, MD, MSc, MPH, PhD
New data show Indigenous communities face higher rates of gallbladder and biliary cancers, with emerging research suggesting distinct genetic and biological drivers in Alaska Native and Pacific Islander populations.
Why Indigenous Communities Face Higher Cancer Rates
By Jin Mou, MD, MSc, MPH, PhD
New data show Indigenous communities face higher rates of gallbladder and biliary cancers, with emerging research suggesting distinct genetic and biological drivers in Alaska Native and Pacific Islander populations.
Why Indigenous Communities Face Higher Cancer Rates
By Jin Mou, MD, MSc, MPH, PhD
New data show Indigenous communities face higher rates of gallbladder and biliary cancers, with emerging research suggesting distinct genetic and biological drivers in Alaska Native and Pacific Islander populations.
Can a Blood Test Detect Cancer Earlier? What to Know About Liquid Biopsy
By The Cancer News Team
A new study suggests multicancer blood tests could shift cancer diagnoses to earlier stages. Here’s what liquid biopsy is, how MCED tests work, current FDA approvals, benefits, risks, and what patients should know.
Can a Blood Test Detect Cancer Earlier? What to Know About Liquid Biopsy
By The Cancer News Team
A new study suggests multicancer blood tests could shift cancer diagnoses to earlier stages. Here’s what liquid biopsy is, how MCED tests work, current FDA approvals, benefits, risks, and what patients should know.
Can a Blood Test Detect Cancer Earlier? What to Know About Liquid Biopsy
By The Cancer News Team
A new study suggests multicancer blood tests could shift cancer diagnoses to earlier stages. Here’s what liquid biopsy is, how MCED tests work, current FDA approvals, benefits, risks, and what patients should know.
Dr. Julia Zhang on Challenging Treatment Dogma: Early Bispecific Antibody Use in Relapsed Myeloma
By The Cancer News Team
An expert panel at Best of Hematology & Breast Cancer 2026 debates early use of bispecific antibodies versus CAR T-cell therapy in an 83-year-old patient with relapsed multiple myeloma.
Dr. Julia Zhang on Challenging Treatment Dogma: Early Bispecific Antibody Use in Relapsed Myeloma
By The Cancer News Team
An expert panel at Best of Hematology & Breast Cancer 2026 debates early use of bispecific antibodies versus CAR T-cell therapy in an 83-year-old patient with relapsed multiple myeloma.
Dr. Julia Zhang on Challenging Treatment Dogma: Early Bispecific Antibody Use in Relapsed Myeloma
By The Cancer News Team
An expert panel at Best of Hematology & Breast Cancer 2026 debates early use of bispecific antibodies versus CAR T-cell therapy in an 83-year-old patient with relapsed multiple myeloma.